Comparative Pharmacology
Head-to-head clinical analysis: CHILDREN S CETIRIZINE HYDROCHLORIDE ALLERGY versus DECABID.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CHILDREN S CETIRIZINE HYDROCHLORIDE ALLERGY versus DECABID.
CHILDREN'S CETIRIZINE HYDROCHLORIDE ALLERGY vs DECABID
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Cetirizine is a selective antagonist of peripheral histamine H1 receptors. It inhibits the H1 receptor-mediated effects of histamine, reducing symptoms such as pruritus, sneezing, rhinorrhea, and urticaria. It also decreases eosinophil chemotaxis and adhesion molecule expression.
Decabid is a combination of chlorpheniramine (antihistamine) and pseudoephedrine (decongestant). Chlorpheniramine competitively antagonizes histamine at H1 receptors, reducing allergic symptoms. Pseudoephedrine acts as a sympathomimetic agent, stimulating alpha-adrenergic receptors to cause vasoconstriction, reducing nasal congestion.
5-10 mg orally once daily; max 10 mg/day. For children's formulation, typical adult dose applies to patients >12 years.
1 capsule orally every 12 hours; each capsule contains 10 mg phenylephrine hydrochloride and 75 mg carbinoxamine maleate.
None Documented
None Documented
Approximately 8.3 hours (range 6–10 hours) in healthy adults; prolonged in renal impairment (e.g., up to 20 hours).
12 hours (terminal); prolonged to 24 hours in renal impairment (CrCl <30 mL/min)
Renal: ~60% unchanged; fecal: ~10%; minor biliary elimination.
Renal (50% as unchanged drug), fecal (40% as metabolites), biliary (10% as glucuronide conjugates)
Category A/B
Category C
Antihistamine
Antihistamine/Decongestant Combination